Agios Pharmaceuticals (AGIO) Reaches New 12-Month High at $78.68

Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $78.68 and last traded at $78.64, with a volume of 1195037 shares traded. The stock had previously closed at $69.89.

Several research firms have recently issued reports on AGIO. Credit Suisse Group lifted their price target on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer reissued a “buy” rating and issued a $83.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Tuesday, January 16th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Cann reissued a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $77.64.

The company has a market capitalization of $3,810.00, a PE ratio of -11.15 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the previous year, the firm earned ($1.63) EPS. Agios Pharmaceuticals’s revenue was up 26.4% on a year-over-year basis. sell-side analysts anticipate that Agios Pharmaceuticals Inc will post -6.59 EPS for the current fiscal year.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $60.88, for a total transaction of $243,520.00. Following the completion of the sale, the director now directly owns 82,394 shares in the company, valued at approximately $5,016,146.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,130 shares of company stock valued at $5,561,250. Corporate insiders own 5.43% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after purchasing an additional 895,584 shares during the period. Vanguard Group Inc. grew its stake in shares of Agios Pharmaceuticals by 23.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after acquiring an additional 617,379 shares during the period. Capital International Investors grew its stake in shares of Agios Pharmaceuticals by 0.3% during the 3rd quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock valued at $209,470,000 after acquiring an additional 8,294 shares during the period. BlackRock Inc. grew its stake in shares of Agios Pharmaceuticals by 23.5% during the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock valued at $137,648,000 after acquiring an additional 508,306 shares during the period. Finally, State Street Corp grew its stake in shares of Agios Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock valued at $67,036,000 after acquiring an additional 97,220 shares during the period. Institutional investors and hedge funds own 93.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Agios Pharmaceuticals (AGIO) Reaches New 12-Month High at $78.68” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/01/22/agios-pharmaceuticals-agio-reaches-new-12-month-high-at-78-68.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply